CANNAINVESTOR Magazine Unites States March / April 2019 | Page 188

You of course can do your own online searches but remember to stick to reputable sources and avoid content from paid promoters or those that are over-hyping the cannabis sector in general on forums such as social media, subreddit, and seeking alpha.

Even more astonishing (and you will see why I used that term) is USA Patent US6630507B1 issued in April of 1999. I am going to reprint its abstract here word for word and I want you to pay close attention to what was known as far back as 1999 – before the Endogenous Cannabinoid System’s discovery:

Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidiol, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention. A particular disclosed class of cannabinoids useful as neuroprotective antioxidants is formula (I) wherein the R group is independently selected from the group consisting of H, CH3, and COCH3.

Now for just one element of what it is being claimed by this 1999 patent:

We claim:

1. A method of treating diseases caused by oxidative stress, comprising administering a therapeutically effective amount of a cannabinoid that has substantially no binding to the NMDA receptor to a subject who has a disease caused by oxidative stress.

188